Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts.
about
Impact of antiretroviral therapy (ART) timing on chronic immune activation/inflammation and end-organ damageMight dolutegravir be part of a functional cure for HIV?Impact of Chronic HIV/SIV Infection on T Follicular Helper Cell Subsets and Germinal Center HomeostasisSwitch to Ritonavir-Boosted versus Unboosted Atazanavir plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical PracticeReview: Influence of ART on HIV geneticsAntiretroviral treatment in HIV-infected infants and young children: novel issues raised by the Mississippi babyFrench 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults.Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys.Long-term antiretroviral treatment initiated at primary HIV-1 infection affects the size, composition, and decay kinetics of the reservoir of HIV-1-infected CD4 T cellsHIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapyHIV type 1 (HIV-1) proviral reservoirs decay continuously under sustained virologic control in HIV-1-infected children who received early treatmentIs the central nervous system a reservoir of HIV-1?Influence of the timing of antiretroviral therapy on the potential for normalization of immune status in human immunodeficiency virus 1-infected individuals.Rate and determinants of residual viremia in multidrug-experienced patients successfully treated with raltegravir-based regimens.Exploring the potential of monoclonal antibody therapeutics for HIV-1 eradication.Influence of age at virologic control on peripheral blood human immunodeficiency virus reservoir size and serostatus in perinatally infected adolescentsDoes transient cART started during primary HIV infection undermine the long-term immunologic and virologic response on cART resumption?Post-treatment control of HIV infection.Association between first-year virological response to raltegravir and long-term outcomes in treatment-experienced patients with HIV-1 infection.CD4:CD8 ratio as a frontier marker for clinical outcome, immune dysfunction and viral reservoir size in virologically suppressed HIV-positive patients.A Randomized Trial of Time-Limited Antiretroviral Therapy in Acute/Early HIV Infection.Structured Treatment Interruptions and Low Doses of IL-2 in Patients with Primary HIV Infection. Inflammatory, Virological and Immunological Outcomes.Discordant Immune Response with Antiretroviral Therapy in HIV-1: A Systematic Review of Clinical Outcomes.The Effect of Therapeutic HIV Vaccination With ALVAC-HIV With or Without Remune on the Size of the Viral Reservoir (A CTN 173 Substudy).Early Antiretroviral Therapy Is Associated with Lower HIV DNA Molecular Diversity and Lower Inflammation in Cerebrospinal Fluid but Does Not Prevent the Establishment of Compartmentalized HIV DNA PopulationsImpact of a decade of successful antiretroviral therapy initiated at HIV-1 seroconversion on blood and rectal reservoirs.Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification.The HIV Cure Research Agenda: The Role of Mathematical Modelling and Cost-Effectiveness Analysis.Peripheral T Follicular Helper Cells Are the Major HIV Reservoir within Central Memory CD4 T Cells in Peripheral Blood from Chronically HIV-Infected Individuals on Combination Antiretroviral Therapy.Advances and hope for perinatal HIV remission and cure in children and adolescents.HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trialLEDGIN-mediated Inhibition of Integrase-LEDGF/p75 Interaction Reduces Reactivation of Residual Latent HIVImpact of early cART in the gut during acute HIV infectionInitiation of antiretroviral therapy before detection of colonic infiltration by HIV reduces viral reservoirs, inflammation and immune activation.Towards an HIV cure: science and debate from the International AIDS Society 2013 symposium.Monitoring Integration over Time Supports a Role for Cytotoxic T Lymphocytes and Ongoing Replication as Determinants of Reservoir Size.Virological Blips and Predictors of Post Treatment Viral Control After Stopping ART Started in Primary HIV Infection.Post-treatment control or treated controllers? Viral remission in treated and untreated primary HIV infection.Understanding HIV compartments and reservoirs.HIV-1 latency: an update of molecular mechanisms and therapeutic strategies.
P2860
Q27014077-244B678D-E753-4C8D-A415-27453C83080BQ28071420-B043B3B2-0F44-470B-B76A-F97866716CFFQ28077701-9292D087-39AF-4FA5-9E11-7B11693664F7Q28553066-BC5D64BC-6804-4FFD-A5B1-74313A0133FCQ28649848-05067407-A21E-4CB9-8B3F-A1950EC8DE59Q33557037-1C76EAAD-81EC-4E8C-AED8-94E60B0B91B8Q33775397-DC95A2A9-63D2-4E48-8044-4620349801D0Q34020988-160F6A3C-FE08-4866-BC0B-9E57B6351467Q34059612-BA4574AD-9BA5-4672-9263-DA95DD0BA256Q34354110-8FB9C3EB-C896-4FD0-9873-20110DEE62BEQ34430211-29489201-C31B-40C3-91DD-1EAA5737F6C7Q34434339-176EEE8F-6721-4E25-9C32-C4144D022968Q34666498-96CC6858-400A-4EC4-909C-F5EE51E3F4F0Q34869426-E8C46991-0BA4-401C-8D03-B0D75249DE17Q34869927-3384AA4F-96B6-4038-8827-FD558C38EF79Q35072975-F32292DC-4193-40D4-848B-DC331EC33132Q35491883-82ADF8A4-AC38-465A-8C91-1E49369C3E98Q35567047-1DA6ABA5-4CE9-4B66-AFEC-52DB9A2FADB7Q35577906-0BF060EC-7DD0-477D-8A11-35721A6C0842Q35801549-601DDEFE-8706-4AA1-B462-4D7CF8F70DC9Q35850919-C1BC1B2F-F648-4F0F-8FAC-5F4D8D58C97BQ35862206-1337C117-D60F-4382-8072-EB9D3EC12830Q36047903-193093A1-B736-49A4-97A0-7CEE82DC9641Q36080407-162EDBF0-ADF7-4DF5-9F46-8FB7FD3A06E1Q36238501-EA566A17-3752-476E-9F44-39CE41322A99Q36311695-9B715893-9443-472E-AA14-C31DB28C3862Q36509593-047B5CD3-DAED-4B2A-8A97-3CF79F2918C3Q36567107-394B5DC7-FF6B-4E04-A838-E4D78DFD4C33Q36736667-13B044F8-864B-4C40-A59C-9895CA59466BQ36737063-6F52B6B2-477C-400A-A8CF-744A874BD266Q36986644-F2DB076D-581F-4474-92A5-C68386EDAE6FQ37035177-71E57BF9-3831-4E53-8143-B46233E2FF8FQ37109215-9CF182DB-E2DC-4355-8531-F68EA98B30D9Q37262786-DC417364-3A8F-4CFB-BEFE-A8FDF59C80D4Q37309568-4D4B47D3-BF61-4DD8-A2AA-1EA2A1EA11F0Q37415458-79268A77-B9B7-46B2-8281-FC3A8493ADC4Q37582477-78BBB95E-7159-4019-B8CE-57F97FF63B76Q37613230-0E215010-77D5-4C7D-98B6-DCC52D66BB30Q38204313-B9CAB2E1-1431-41B0-A663-3E80DD257AF0Q38204866-4A7FA6AE-4B43-40B3-A122-6645EF53D3C9
P2860
Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Long-term antiretroviral thera ...... oirs and normal T cell counts.
@en
Long-term antiretroviral thera ...... oirs and normal T cell counts.
@nl
type
label
Long-term antiretroviral thera ...... oirs and normal T cell counts.
@en
Long-term antiretroviral thera ...... oirs and normal T cell counts.
@nl
prefLabel
Long-term antiretroviral thera ...... oirs and normal T cell counts.
@en
Long-term antiretroviral thera ...... oirs and normal T cell counts.
@nl
P2093
P2860
P356
P1476
Long-term antiretroviral thera ...... oirs and normal T cell counts.
@en
P2093
AC32 (Coordinated Action on HI ...... t les Hépatites Virales (ANRS)
Adeline Mélard
Catherine Mille
Eric Legac
Gwenaël Le Moal
Jean-Paul Viard
Laurent Hocqueloux
Mohamadou Niang
Sophie Jacquot
Thierry Prazuck
P2860
P304
P356
10.1093/JAC/DKS533
P407
P577
2013-01-20T00:00:00Z